Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 7Colorectal Neoplasms 5Digestive System Neoplasms 4Pancreatic Neoplasms 3Neoplasms, Glandular and Epithelial 3Neoplasms by Site 3Digestive System Diseases 3Pancreatic Diseases 2Neoplasms by Histologic Type 2Endocrine Gland Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Thymus Neoplasms 1Stomach Neoplasms 1Rectal Diseases 1Pancreatic cancer, adult 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intestinal Neoplasms 1Intestinal Diseases 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1

Interventions

Gemcitabine 27Fluorouracil 25Oxaliplatin 21Cisplatin 19Leucovorin 17Bevacizumab 16Docetaxel 13Albumin-Bound Paclitaxel 13130-nm albumin-bound paclitaxel 13Paclitaxel 12Capecitabine 12Irinotecan 11Carboplatin 9pembrolizumab 7Nivolumab 7Radiotherapy 6Pemetrexed 6Erlotinib Hydrochloride 6Cyclophosphamide 6Trastuzumab 5Ramucirumab 5Ipilimumab 4Everolimus 4Crizotinib 4Cetuximab 4vandetanib 3trastuzumab deruxtecan 3sargramostim 3folfirinox 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma × napabucasin × Clear all
NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡